Efgartigimod Offers Hope in Chronic Inflammatory Demyelinating Polyneuropathy

(MedPage Today) -- PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with diagnosed chronic inflammatory...
Source: MedPage Today Neurology - Category: Neurology Source Type: news
More News: Brain | CIDP | Neurology